Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://med.amegroups.com/article/view/10.21037/med-22-ab014/coif). XMR reports personal fees from Astra Zeneca, MSD, BMS and Pfizer in speakers bureaus and educational events concept, and personal fees from Astra Zeneca and Boehringer in Advisory role concept. He also reports support for attending meetings from Roche and BMS. The other authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
Cite this abstract as: Mielgo-Rubio X, Hernando Polo S, Jiménez Aguilar E, Olier Garate C, Hurtado Nuño A, Moreno Muñoz D, Sánchez Becerra MV, González López AM, Esteban García M, Robles Bermejo T, Barón M, Hernando Trancho F, Ramón Jarabo J, Cámara Vicario JC. Effective somatostatin analogs in a case of advanced thymoma with no uptake in the octreotide scan. Mediastinum 2022;6:AB014.